|
|
||||||||
1 Division of Clinical Virology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
2 Department of Biochemistry, Biomedical Center, Uppsala University, Uppsala, Sweden
3 Division of Clinical Chemistry, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Correspondence
Anders Vahlne
Anders.Vahlne{at}labmed.ki.se
The capsid protein (CA or p24) of human immunodeficiency virus type 1 (HIV-1) plays a major role both early and late in the virus replication cycle. Many studies have suggested that the C-terminal domain of this protein is involved in dimerization and proper assembly of the viral core. Point mutations were introduced in two conserved sites of this region and their effects on viral protein expression, particle assembly and infectivity were studied. Eight different mutants (L205A+P207A, L205A, P207A, 223GPG225AAA, G223A, P224A, G225A and V221G) of the infectious clone pNL4-3 were constructed. Most substitutions had no substantial effect on HIV-1 protein synthesis, yet they impaired viral infectivity and particle production. The two mutants P207A and V221G also had a profound effect on GagPol protein processing in HeLatat cells. However, these results were cell line-specific and GagPol processing of P207A was not affected in 293T cells. In HeLatat cells, no virus particles were detected with the P207A mutation, whereas the other mutant virus particles were heterogeneous in size and morphology. None of the mutants showed normal, mature, conical core structures in HeLatat cells. These results indicate that the two conserved sequences in the C-terminal CA domain are essential for proper morphogenesis and infectivity of HIV-1 particles.
This article has been cited by other articles:
![]() |
W.-H. Liao, K.-J. Huang, Y.-F. Chang, S.-M. Wang, Y.-T. Tseng, C.-C. Chiang, J.-J. Wang, and C.-T. Wang Incorporation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase into Virus-Like Particles J. Virol., May 15, 2007; 81(10): 5155 - 5165. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Adamson, S. D. Ablan, I. Boeras, R. Goila-Gaur, F. Soheilian, K. Nagashima, F. Li, K. Salzwedel, M. Sakalian, C. T. Wild, et al. In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat) J. Virol., November 15, 2006; 80(22): 10957 - 10971. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. V. Ryzhova, R. M. Vos, A. V. Albright, A. V. Harrist, T. Harvey, and F. Gonzalez-Scarano Annexin 2: a Novel Human Immunodeficiency Virus Type 1 Gag Binding Protein Involved in Replication in Monocyte-Derived Macrophages J. Virol., March 15, 2006; 80(6): 2694 - 2704. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |